glutathione s-transferases Frontiers Glutathione S-transferase π: a potential
Description
10.1016/0162-0134(92)84013-d 3 ApostolopoulosV.BojarskaJ.ChaiT
The figure 25.3 % surpasses: Tirzepatide SURMOUNT-1: 22.5 % Semaglutide STEP-1: 14.9 % Retatrutide Phase 2: 24.2 % (comparable, but Phase 3 results for Retatrutide are still lacking) It raises the question whether CagriSema will be the first molecule with an effect truly comparable to bariatric surgery (typically 2530 % reduction)
Participation of older adults in cancer clinical trials has not changed over time (Sedrak et al., 2021)
Outcome measures include biomechanical testing (load to failure, stiffness), histological scoring (collagen organization, fibroblast density), and functional assessment (gait analysis, range of motion)
